Literature DB >> 23562596

Identification of novel SIRT3 inhibitor scaffolds by virtual screening.

Heikki S Salo1, Tuomo Laitinen, Antti Poso, Elina Jarho, Maija Lahtela-Kakkonen.   

Abstract

SIRT3 is a member of the sirtuin family of histone deacetylases. It is a mitochondrial protein, which has an important role in metabolic homeostasis but it may also act as a tumor suppressor or promoter. Increased SIRT3 transcription has been associated with node-positive breast cancer and oral squamous cell carcinoma. To identify novel SIRT3 inhibitors we have established a virtual screening workflow by using shape-based filtering and flexible docking protocol. The Chembridge database was screened and 40 molecules were selected and tested in an in vitro assay. Two novel scaffolds were identified among the tested hits. The 5-amino-2-phenyl-benzoxazole scaffold was selected for further structure-activity studies and a series of its analogs was tested. The SIRT3 inhibition for this series ranged between 13% and 71%.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23562596     DOI: 10.1016/j.bmcl.2013.03.033

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  16 in total

1.  A Novel Sirtuin-3 Inhibitor, LC-0296, Inhibits Cell Survival and Proliferation, and Promotes Apoptosis of Head and Neck Cancer Cells.

Authors:  Turki Y Alhazzazi; Pachiyappan Kamarajan; Yanli Xu; Teng Ai; Liqiang Chen; Eric Verdin; Yvonne L Kapila
Journal:  Anticancer Res       Date:  2016-01       Impact factor: 2.480

2.  Comparative modeling and benchmarking data sets for human histone deacetylases and sirtuin families.

Authors:  Jie Xia; Ermias Lemma Tilahun; Eyob Hailu Kebede; Terry-Elinor Reid; Liangren Zhang; Xiang Simon Wang
Journal:  J Chem Inf Model       Date:  2015-02-09       Impact factor: 4.956

Review 3.  Using mitochondrial sirtuins as drug targets: disease implications and available compounds.

Authors:  Melanie Gertz; Clemens Steegborn
Journal:  Cell Mol Life Sci       Date:  2016-03-23       Impact factor: 9.261

Review 4.  Sirtuin activators and inhibitors: Promises, achievements, and challenges.

Authors:  Han Dai; David A Sinclair; James L Ellis; Clemens Steegborn
Journal:  Pharmacol Ther       Date:  2018-03-22       Impact factor: 12.310

5.  The sirtuin family in cancer.

Authors:  Luis Filipe Costa-Machado; Pablo J Fernandez-Marcos
Journal:  Cell Cycle       Date:  2019-07-25       Impact factor: 4.534

Review 6.  Sirtuin-3 (SIRT3), a therapeutic target with oncogenic and tumor-suppressive function in cancer.

Authors:  Y Chen; L L Fu; X Wen; X Y Wang; J Liu; Y Cheng; J Huang
Journal:  Cell Death Dis       Date:  2014-02-06       Impact factor: 8.469

7.  Mitochondrial aldehyde dehydrogenase obliterates insulin resistance-induced cardiac dysfunction through deacetylation of PGC-1α.

Authors:  Nan Hu; Jun Ren; Yingmei Zhang
Journal:  Oncotarget       Date:  2016-11-22

Review 8.  Computer-Aided Drug Design in Epigenetics.

Authors:  Wenchao Lu; Rukang Zhang; Hao Jiang; Huimin Zhang; Cheng Luo
Journal:  Front Chem       Date:  2018-03-12       Impact factor: 5.221

9.  The Role of SIRT3 in the Brain Under Physiological and Pathological Conditions.

Authors:  Elena Sidorova-Darmos; Rosa Sommer; James H Eubanks
Journal:  Front Cell Neurosci       Date:  2018-07-25       Impact factor: 5.505

10.  Toxoplasma gondii GRA8 induces ATP5A1-SIRT3-mediated mitochondrial metabolic resuscitation: a potential therapy for sepsis.

Authors:  Ye-Ram Kim; Jae-Sung Kim; Jin-Seung Yun; Sojin Kim; Sun Young Kim; Kiseok Jang; Chul-Su Yang
Journal:  Exp Mol Med       Date:  2018-03-30       Impact factor: 8.718

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.